Entresto is a prescription medication used primarily to treat certain forms of chronic heart failure. It is classified as a neprilysin inhibitor that enhances the levels of beneficial cardiovascular peptides. The drug also contains sacubitril, which is combined with valsartan, an angiotensin ii receptor blocker. Together they increase circulating natriuretic peptides and block the vasoconstrictive effects of angiotensin ii. This dual action promotes vasodilation, reduces sodium and water retention, and lowers cardiac workload. Pharmacologically, neprilysin inhibition prevents the breakdown of these peptides, allowing them to exert antihypertensive, anti-fibrotic, and natriuretic effects. The resulting hemodynamic improvements translate into clinical benefits such as reduced hospitalizations and prolonged survival in eligible patients.

Entresto is a combination medication that contains sacubitril and valsartan in a fixed dose. Sacubitril is a prodrug that is converted into sacubitrilat, a neprilysin inhibitor that increases levels of beneficial peptides. Valsartan is an angiotensin ii receptor blocker that prevents the vasoconstrictive effects of angiotensin ii. Together they reduce blood pressure and decrease the workload of the heart in patients with chronic heart failure. By blocking neprilysin, sacubitrilat enhances the concentration of natriuretic peptides that promote vasodilation, natriuresis, and inhibition of remodeling. This dual action leads to improved cardiac function, lower hospitalization rates, and reduced mortality in heart failure patients. The pharmacokinetic properties of both components are designed to provide complementary inhibition of the renin-angiotensin system and neprilysin activity.

Entresto may cause dizziness or lightheadedness, especially after the first dose. A dry cough is reported by some patients taking the medication. Low blood pressure can occur, leading to faintness or weakness. Elevated potassium levels, known as hyperkalemia, have been observed in certain individuals. Headaches are among the frequently cited side effects. Fatigue or tiredness may develop during treatment. Some patients experience kidney function changes reflected in laboratory tests.

Entresto may cause dizziness in some patients. It can lead to low blood pressure especially after the first dose. A persistent dry cough has been reported as a side effect. Elevated blood potassium levels can occur in certain individuals. Some people experience mild nausea or stomach discomfort. Headache is another frequently observed symptom. Fatigue or feeling unusually weak may develop during treatment. Rarely, kidney function tests may show temporary changes.